New findings from the randomized Phase III STAMPEDE trial took the stage at #ESMO26 today. Here’s a recap from a session where Sarah Howlett, M.B.B.S., University College London (@ucl), presented results from a combination analysis of STAMPEDE and real-world datasets.

The talk highlighted how the Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk #ProstateCancer, whose disease had not spread to lymph nodes.

| Primary Takeaways |

🔹 Transcriptomic signatures showed consistent associations with metastatic outcomes across both STAMPEDE and real-world datasets.

🔹 Higher Decipher scores identified patients with higher rates of distant metastasis and those most likely to benefit from the addition of abiraterone.

🔹 Lower Decipher scores correlated with lower rates of distant metastasis, potentially providing means for guiding safe treatment de-escalation.

| Some Thank You’s |

💙 We’re grateful to Dr. Howlett for sharing this research with the oncology community and for her continued dedication to improving care for the millions of men living with prostate cancer worldwide.

💙 Thank you to everyone who joined the session and to the investigators, site teams, and participants whose contributions made this research possible.

| Additional Resources |

🔗 Event information - https://www.veracyte.com/company/event/esmo-2026/

🔗 Decipher Prostate Genomic Classifier - https://www.veracyte.com/tests/decipher-prostate/providers/

#PrecisionOncology #ClinicalResearch #RealWorldData #DecipherProstate #TeamVeracyte

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/